Stryker Corporation SYK
- Market cap
- $103.9B
- P/E
- 28.0×
Follow SYK
Stryker Corporation (SYK) Return on invested capital
Stryker Corporation's return on invested capital over the twelve months to 30 June 2026 was 9.76%, up 0.8 percentage points from fiscal 2025 (8.94%). Over the past ten years it has ranged from 5.78% (fiscal 2020) to 13.8% (fiscal 2015); the current reading is higher than 73% of that period. That is above the Medical Devices industry median of −10.3% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Annual
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 8.94% | 1.19 |
| FY2024 | 7.75% | (0.77) |
| FY2023 | 8.52% | 2.12 |
| FY2022 | 6.40% | (0.24) |
| FY2021 | 6.64% | 0.86 |
| FY2020 | 5.78% | (2.93) |
| FY2019 | 8.71% | (0.15) |
| FY2018 | 8.86% | (1.10) |
| FY2017 | 9.96% | (0.43) |
| FY2016 | 10.4% | (3.41) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| DXCM DexCom, Inc. compare | 37.1% |
| EW Edwards Lifesciences Corporation compare | 12.8% |
| SYK Stryker Corporation | 9.76% |
| GEHC GE HealthCare Technologies Inc. compare | 8.37% |
| STE STERIS plc compare | 8.27% |
| BSX Boston Scientific Corporation compare | 6.96% |
| PHG Koninklijke Philips N.V. compare | 6.69% |
| MDT Medtronic PLC compare | 6.04% |
| ABT Abbott Laboratories compare | 5.83% |
| Medical Devices industry median | −10.3% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on SYK
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement